Prior to Dantari, Tim was the Global Head of Development Operations for Early Development at Amgen. In this role, Tim oversaw all therapeutic areas with 40+ assets focused in translation science and was key in building a scientifically focused team to deliver the complex portfolio.
Prior to Amgen, Tim had multiple roles within Roche and Genentech, bringing a unique combination of global operational and regulatory leadership. He had a range of roles in key leadership positions within Medical Affairs, Pharma Development, Finance, and Business Analytics working through transformational change. In his capacity, he covered the range of Phase I-IV clinical studies. In addition, he led the global affiliate network on regulatory and operational requirements for the various sourcing models. At Genentech he led key oncology and CNS assets as a clinical program leader.
Tim began his career with his PhD degree from the University of Texas, Health Science Center with his scientific research focused on CNS disorders. He earned a prestigious Alexander von Humboldt grant in Germany at the Friedrich Alexander University followed by being on faculty at the University of Munich.